LENSAR, Inc.

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

LNSRNasdaqHealthcareMedical Devices
$5.61 -0.06 (-1.06%)

Company Overview

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Price Chart

Historical Trend (Absolute Values)
LNSR Price
05/1505/2606/02

Financial Metrics

Market Capitalization$67.91M
P/E Ratio
Earnings Per Share (EPS)-$1
Dividend Yield
Beta (Volatility)0.844
Price to Book (P/B)6.2892
52-Week Range$5.06 - $13.67

LAST SCRARED: June 2, 2026

Compare LNSR

Analyze valuation multiples and growth parameters side-by-side with other public equities.

Compare Stock Now
VersusHub

© 2026 VersusHub. All rights reserved.